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The era of biosimilars in oncology has just arrived. 
In February 2017, the European Medicines Agency 
(EMA) registered the first biosimilar for rituximab 
(Truxima®). In April, two additional biosimilars for 
rituximab (Rixathon® and Riximyo®) received a pos-
itive recommendation from the European Committee 
for Medicinal Products for Human Use (CHMP). This 
recommendation is a prerequisite for the registration 
of these drugs by the EMA, which is expected in June 
this year. 
Monoclonal antibodies introduced into the oncol-
ogy armamentarium at the end of the 1990s represent 
a breakthrough in the treatment of many cancers. How-
ever, the cost of therapies based on these drugs has 
significantly limited their widespread use, especially 
in countries with low expenditure on oncological 
treatment. For most anticancer drugs, being simplex 
chemical compounds (chemotherapeutics, hormonal 
drugs, small molecule kinase inhibitors), the expiry of 
patent protection was associated with the immediate 
emergence of generic drugs. This naturally led in a short 
time to a significant price reduction of original drugs 
and improved availability of new methods of systemic 
treatment. The production of generic drugs that are 
identical copies of the original ones is relatively easy 
because it is based on the synthesis of simple molecules 
with low molecular weight. The condition for marketing 
authorisation of a generic drug is only to show the same 
composition, form, bioavailability, and pharmacological 
properties as the original drug. 
Compared to generic drugs, the production of bio-
similars is a big challenge. The process of producing 
a biological drug based on living organisms (genetically 
modified cells) is extremely complex. The final product is 
a protein that owes its biological functions to a particular 
spatial structure. Spatial conformation is determined not 
only by the corresponding aminoacids sequence in the 
polypeptide chains, but above all by the processes that 
take place during post-translational protein modification 
(e.g. proteolytic processing, hydroxylation, glycosylation, 
phosphorylation, ubiquitination, or poly-rybosylation). 
It is then that a variety of sugar residues are attached to 
polypeptide chains, being responsible for the formation 
of bonds between polypeptide chains that give the pro-
tein an appropriate spatial structure that determines its 
normal – expected – function. In the case of antibodies, 
the appropriate spatial structure determines the critical 
pharmacological properties of these proteins, such as 
antigenic specificity, immune system affinity, half-life, 
or immunogenicity. 
A potentially large number of variables (physical, 
chemical, and biological factors) can significantly alter 
the characteristics of the produced biological drug, even 
as a result of the subtle modifications of the functions 
of cells cultured in bio-reactors. Accordingly, manufac-
turing of a biological drug requires the use of highly so-
phisticated control and validation methods to ensure the 
expected pharmacologic activity of the end-product. The 
ideal situation is therefore the production of a biological 
drug under certain and unaltered conditions that allow 
exactly the same end-product to be obtained in a long-
-term perspective. However, taking into consideration 
the fact that biological drugs are produced in living cells 
whose functions depend on a large number of variables 
(e.g. age of cells, composition of the medium, ambient 
temperature, atmospheric pressure, electromagnetic ra-
diation), it is known that the characteristics of biological 
drugs from one manufacturer can change over time, and 
the same biological drugs from different manufacturers 
may have minor differences. For example, due to the 
possibility of minor differences between the prepara-
tions of Herceptin® produced in Europe and the United 
States, some clinical trials compared at the same time 
biosimilars with trastuzumab-US and trastuzumab-EU. 
Contrary to generic drugs, in case of biosimilars it 
is not enough to show that the drug is identical to the 
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original according to chemical structure (e.g. the amino 
acid sequence in the polypeptide chains). As mentioned 
above, in case of biological drugs, the same chemical 
structure does not mean the same spatial structure, the 
same biological effect, and thus the same antitumor po-
tential and safety profile. For biosimilars, it is necessary 
not only to prove invariable and optimal conditions of 
production, but first and foremost a comparable efficacy 
and safety should be demonstrated in clinical trials. For 
this reason, the marketing authorisation of biosimilars 
is a far more complicated, time-consuming, and costly 
process compared to generic drugs. 
Regulatory agencies authorising the commerciali-
sation of biosimilars pay special attention to numerous 
aspects related to the introduction of these drugs into 
clinical practice. First of all, they recommend long-term 
observation of patients with respect to possible delayed, 
atypical side effects, which could potentially be revealed. 
Every biologic drug, both original and biosimilar, is 
subject of special post-marketing surveillance (black 
triangle labelling). Due to the unavoidable differences in 
spatial conformation of the proteins and, consequently, 
slight differences in biological characteristics between 
particular biosimilars and original drugs, automatic 
substitution of biological drugs during therapy (from 
the original to biosimilar or vice versa) is not allowed. 
The lack of possibility for automatic substitution of 
corresponding biological drugs is primarily due to safety 
aspects and the need for accurate monitoring and re-
porting of adverse reactions, which is one of the basic 
principles of systemic treatment in the biosimilar era. 
The decision to change the drug should be made by the 
physician, based on current medical knowledge and in 
each case obtaining the patient’s informed consent for 
such a procedure. 
The introduction of biosimilar drugs is undoubtedly 
a big challenge for oncologists and pharmacists. They have 
to be aware not only of what biological drugs are and how 
much their functions depend on storage conditions, prepa-
ration and administration to patients, but they also have to 
always remember that biosimilars are not generic drugs.
Biosimilars in oncology represent great opportunity 
to reduce the significant limitations in access to mod-
ern systemic therapies without a significant burden on 
the payer’s budget, provided that specific policies are 
followed. The expected increase in the availability of 
modern pharmacotherapy should not only improve 
the efficacy of systemic treatment in a large number 
of patient populations but, above all, by significantly 
reducing the costs of currently used drugs should finally 
allow reimbursement of long awaited new innovative 
biological therapies.
